Navigating Early Phase CNS-Active Drug Development With Dr. Beatrice Setnik, CSO

Early development of CNS-active drugs requires in-depth clinical expertise. Altasciences’ Dr. Beatrice Setnik, Chief Scientific Officer, explains how this process can be navigated in early-stage development.

The presentation focuses on the following:

• Risk/benefit evaluations for CNS-active drugs and cannabinoids
• Regulatory considerations and requirements
• The importance of including assessments to receive safety information
• How and when to evaluate Human Abuse Potential (HAP) and physical dependence potential
• How drugs are scheduled